Inhibition of mitochondrial protein translation sensitizes melanoma cells to arsenic trioxide cytotoxicity via a reactive oxygen species dependent mechanism

[1]  J. Kirkwood,et al.  A phase II study of arsenic trioxide (ATO) in patients with metastatic melanoma , 2007 .

[2]  B. Cooperman,et al.  Kinetically competent intermediates in the translocation step of protein synthesis. , 2007, Molecular cell.

[3]  R. Moss,et al.  Efficacy and safety of melphalan, arsenic trioxide and ascorbic acid combination therapy in patients with relapsed or refractory multiple myeloma: a prospective, multicentre, phase II, single‐arm study , 2006, British journal of haematology.

[4]  Nicholas D Bonawitz,et al.  Defective Mitochondrial Gene Expression Results in Reactive Oxygen Species-Mediated Inhibition of Respiration and Reduction of Yeast Life Span , 2006, Molecular and Cellular Biology.

[5]  A. T. Bentley,et al.  Inhibition of Mammalian Mitochondrial Protein Synthesis by Oxazolidinones , 2006, Antimicrobial Agents and Chemotherapy.

[6]  Tsutomu Suzuki,et al.  Antibiotic susceptibility of mammalian mitochondrial translation , 2005, FEBS letters.

[7]  L. Camacho,et al.  A phase II trial of arsenic trioxide in patients with metastatic melanoma , 2005, Cancer.

[8]  Deborah Schrag,et al.  Annual report to the nation on the status of cancer, 1975-2002, featuring population-based trends in cancer treatment. , 2005, Journal of the National Cancer Institute.

[9]  M. B. Davis,et al.  Trolox selectively enhances arsenic-mediated oxidative stress and apoptosis in APL and other malignant cell lines. , 2005, Blood.

[10]  P. Venugopal,et al.  Arsenic trioxide and thalidomide combination produces multi-lineage hematological responses in myelodysplastic syndromes patients, particularly in those with high pre-therapy EVI1 expression. , 2004, Leukemia research.

[11]  O. Ogawa,et al.  Enhancement of arsenic trioxide-induced apoptosis in renal cell carcinoma cells by L-buthionine sulfoximine. , 2004, International journal of oncology.

[12]  S. Mader,et al.  Glutathione depletion overcomes resistance to arsenic trioxide in arsenic-resistant cell lines , 2003, Leukemia.

[13]  Keunchil Park,et al.  Arsenic trioxide inhibits the growth of A498 renal cell carcinoma cells via cell cycle arrest or apoptosis. , 2003, Biochemical and biophysical research communications.

[14]  M. Atkins,et al.  Cutaneous malignant melanoma. , 2001, Clinics in dermatology.

[15]  C. Sezgin,et al.  Arsenic trioxide-mediated cytotoxicity and apoptosis in prostate and ovarian carcinoma cell lines. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[16]  P. Pandolfi,et al.  Retinoic acid (RA) and As2O3 treatment in transgenic models of acute promyelocytic leukemia (APL) unravel the distinct nature of the leukemogenic process induced by the PML-RARalpha and PLZF-RARalpha oncoproteins. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[17]  F. Cognetti,et al.  Dacarbazine-based chemotherapy for metastatic melanoma: thirty-year experience overview. , 2000, Journal of experimental & clinical cancer research : CR.

[18]  Y. Y. Lee,et al.  Effect of arsenic trioxide on cell cycle arrest in head and neck cancer cell line PCI-1. , 1999, Biochemical and biophysical research communications.

[19]  M. Rodnina,et al.  Thiostrepton inhibits the turnover but not the GTPase of elongation factor G on the ribosome. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[20]  E. Cao,et al.  Induction of apoptosis and inhibition of human gastric cancer MGC-803 cell growth by arsenic trioxide. , 1999, European journal of cancer.

[21]  Y. Akao,et al.  Arsenic trioxide induces apoptosis in neuroblastoma cell lines through the activation of caspase 3 in vitro , 1999, FEBS letters.

[22]  P. Pandolfi,et al.  Treatment of Acute Promyelocytic Leukemia with Arsenic Trioxide , 2001 .

[23]  N. Davidson,et al.  Specific proteolytic cleavage of poly(ADP-ribose) polymerase: an early marker of chemotherapy-induced apoptosis. , 1993, Cancer research.

[24]  B. Dontje,et al.  Arrest of the proliferation of renal and prostate carcinomas of human origin by inhibition of mitochondrial protein synthesis. , 1986, Cancer research.

[25]  J. Roth,et al.  Production of melanoma-associated antigen(s) by a defined malignant melanoma cell strain grown in chemically defined medium. , 1976, Cancer research.

[26]  S. Waxman,et al.  Malignant cells can be sensitized to undergo growth inhibition and apoptosis by arsenic trioxide through modulation of the glutathione redox system. , 1999, Blood.

[27]  S. Waxman,et al.  Arsenic trioxide selectively induces acute promyelocytic leukemia cell apoptosis via a hydrogen peroxide-dependent pathway. , 1999, Blood.

[28]  T. Naoe,et al.  In vitro studies on cellular and molecular mechanisms of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia: As2O3 induces NB4 cell apoptosis with downregulation of Bcl-2 expression and modulation of PML-RAR alpha/PML proteins. , 1996, Blood.

[29]  B. Steinberg,et al.  Thiostrepton, a new antibiotic. III. In vivo studies. , 1955, Antibiotics annual.